Author
Kari Alitalo
Other affiliations: Mount Sinai Hospital, Toronto, Cornell University, Kyoto University ...read more
Bio: Kari Alitalo is an academic researcher from University of Helsinki. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor C. The author has an hindex of 174, co-authored 817 publications receiving 114231 citations. Previous affiliations of Kari Alitalo include Mount Sinai Hospital, Toronto & Cornell University.
Papers published on a yearly basis
Papers
More filters
1 citations
Patent•
02 Sep 2009
TL;DR: In this paper, an isolated antibody or antibody fragment thereof that binds an extracellular epitope of a fibroblast growth factor receptor-4 (FGFR4) that is expressed by mammalian cells and inhibits cancer cell invasion is presented.
Abstract: The invention provides an isolated antibody or antibody fragment thereof that binds an extracellular epitope of a fibroblast growth factor receptor-4 (FGFR4) that is expressed by mammalian cells and inhibits cancer cell invasion. Optionally, the antibody or fragment thereof binds an epitope of FGFR4 that is bound by monoclonal antibody F90-10C5, or comprises complementarity determining regions identical to those of monoclonal antibody F90-10C5. Also provided are methods of using the antibody or fragment thereof to modulate invasion, ingrowth, or metastasis of cancer cells and treat cancer in a subject. The invention additionally provides a method of identifying an antibody or antibody fragment that inhibits invasiveness.
1 citations
TL;DR: In this paper, growth factors, oncogenes and cancer were discussed in the context of the Scandinavian Journal of Clinical and Laboratory Investigation (SJCLI), Vol. 48, No. sup190, pp. 32-34.
Abstract: (1988). Growth Factors, Oncogenes and Cancer. Scandinavian Journal of Clinical and Laboratory Investigation: Vol. 48, No. sup190, pp. 32-34.
1 citations
Patent•
08 Mar 2005TL;DR: In this article, a method of modulating, regulating and/or stabilizing angiogenesis in a mammal was proposed, in which an active PDGF-D or a polynucleotide encoding anactive PDGFD was administered to the mammal.
Abstract: A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in which an active PDGF-D or a polynucleotide encoding an active PDGF-D is administered to the mammal. The PDGF-D is advantageously co-adminstered with an angiogenic growth factor, such as a member of the VEGF family of growth factors. The claimed method inhibits leakage of blood vessels and is useful, inter alia, for treatment of edemas.
1 citations
TL;DR: These results indicate that the entry route of soluble Ab from the CSF is along the pial–glial basement membrane of arteries, suggesting that soluble Ab reaches the parenchymal extracellular spaces and enters the normal IPAD pathways.
Abstract: veins. Methods: Fluorescently-tagged soluble fixable Ab40 was injected into the cisterna magna of adult male C57BL/6J mice (6–10 weeks or 24–30 month old) and mice were sacrificed at 5 or 30 minutes after injection (n1⁄43 /group). Coronal sections from all areas of the brain were immunostained for markers of basement membranes and smooth muscle actin, followed by confocal microscopy and analyses. Results: Fluorescently-tagged soluble fixable Ab40 was injected into the cisterna magna of adult male C57BL/6J mice (6–10 weeks or 24–30 month old) and mice were sacrificed at 5 or 30 minutes after injection (n1⁄43 /group). Coronal sections from all areas of the brain were immunostained for markers of basement membranes and smooth muscle actin, followed by confocal microscopy and analyses. Conclusions:These results indicate that the entry route of soluble Ab from the CSF is along the pial–glial basement membrane of arteries. By 30 minutes after intracisternal injection, Ab is found in the intramural periarterial drainage pathways, suggesting that soluble Ab reaches the parenchymal extracellular spaces and enters the normal IPAD pathways.
1 citations
Cited by
More filters
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
51,099 citations
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
28,811 citations
28 Jul 2005
TL;DR: PfPMP1）与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。
18,940 citations
TL;DR: It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration.
Abstract: Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
12,395 citations
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Abstract: The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
11,597 citations